Previous close | 0.1200 |
Open | 0.0400 |
Bid | 0.0000 |
Ask | 0.5000 |
Strike | 9.00 |
Expiry date | 2024-07-19 |
Day's range | 0.0200 - 0.3800 |
Contract range | N/A |
Volume | |
Open interest | 1.42k |
ROCKVILLE, Md. & EDMONTON, Alberta, June 05, 2024--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), today announced an oral presentation at the European Alliance of Associations for Rheumatology (EULAR) 2024 taking place in Vienna, Austria June 12-15. The data reinforces previous findings from the AURORA Clinical Program on the safety and effectiveness of LUPKYNIS® (voclosporin), a second generation calcineurin inhibitor (CNI), for the treatment of adult patients with active
ROCKVILLE, Md. & EDMONTON, Alberta, June 04, 2024--Aurinia Addresses Dubious Proposals Put Forth by Lucien Selce
ROCKVILLE, Md. & EDMONTON, Alberta, June 03, 2024--Aurinia Provides Update on Proxy Statement